ArticleJournal of inflammation research2026
Sex-Differentiated Threshold Effects of Homocysteine Levels on CKD Risk in Patients with Hypertension and Coronary Artery Disease.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Elevated homocysteine (Hcy) is a risk factor for hypertension and cardiovascular disease. However, whether increased Hcy elevates chronic kidney disease (CKD) risk specifically in patients with coexisting hypertension and coronary artery disease (CAD) remains unclear. Methods: This study employed a cohort study design and included a total of 1657 patients with coexisting hypertension and CAD. Multivariate Cox regression assessed the association between Hcy and CKD risk. Kaplan-Meier curves compared CKD risk across Hcy tertiles. Restricted cubic splines explored the dose-response relationship and sex-specific threshold effects. C-index, net reclassification improvement (NRI), integrated discrimination improvement (IDI), and random forest (RF) variable importance were used to evaluate the incremental predictive value of Hcy. Mediation analysis examined the role of inflammation. Results: Elevated Hcy was significantly associated with increased CKD risk, with a threshold effect: risk increased notably when Hcy exceeded 18.2 μmol/L in women and 19.0 μmol/L in men. The C-index, IDI, and NRI demonstrated robust predictive performance of Hcy for CKD, and RF identified Hcy as a critical variable. Mediation analysis showed that inflammation played a crucial mediating role, with C-reactive protein and erythrocyte sedimentation rate mediating 15.04% and 6.39% of the effect, respectively. Conclusion: In patients with hypertension and CAD, elevated Hcy is significantly associated with increased CKD risk with a sex-differentiated threshold effect (>18.2 μmol/L in women and >19.0 μmol/L in men). Hcy may serve as an important biomarker for CKD risk stratification. Inflammation partially mediates this process, providing a basis for future mechanistic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.